Effective immunotherapy is also the inhibition of the negative immune-modulator, precisely T-cell immunoglobulin and mucin-domain-containing-3 (TIM3), that is significantly enhanced by the combination with agonistic CD137 antibodies in murine models leading to 60% of cases free of tumor in 90 days from cancer inoculation [29]. Here, TNFRSF9 is linked to neoplasm.